Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 16/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 14/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 13/20 | 0.50 |
| ▸ | CSNK2A3 | Q8NEV1 | 6/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803542 | 0.97 | CSNK2A1 (0.53) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803611 | 0.94 | CSNK2A1 (0.52) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803487 | 0.93 | BRD4 (0.53) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL27319841 | 0.93 | LATS1 (0.60) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803509 | 0.93 | LATS1 (0.60) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL27320162 | 0.92 | BRD4 (0.58) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803552 | 0.92 | BRD4 (0.58) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803505 | 0.87 | CSNK2A1 (0.57) | CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1 | |
| SCHEMBL25371719 | 0.87 | CSNK2A1 (0.56) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B | |
| SCHEMBL30803559 | 0.86 | CSNK2A1 (0.55) | LATS1CSNK2A1BRD4CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | LATS1 589/4885CSNK2A1 5/4885BRD4 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.